Skip to main content

QNTMbio.com

Dihexa (PNB-0408) in the research literature: an angiotensin IV analog and how it is studied

Dihexa is a small, modified peptide developed at Washington State University as a metabolically stable analog of angiotensin IV. Its published record is a handful of rat and cell studies from the originating laboratory, a proposed mechanism involving hepatocyte growth factor, and no human data at all. This guide sets out what it is, what has been reported, where the open questions are, and how to handle it. For laboratory research use only.

What Dihexa is

Dihexa is the common name for N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, a three-unit molecule in which a tyrosine–isoleucine dipeptide carries a hexanoyl group at the N-terminus and a 6-aminohexanoic amide at the C-terminus; the “di-hexa” refers to those two six-carbon groups. It was designed by Joseph Harding and John Wright’s group at Washington State University (its development code is PNB-0408) by trimming and stabilizing the hexapeptide angiotensin IV (Val-Tyr-Ile-His-Pro-Phe) so that the resulting molecule would resist peptidases and cross the blood–brain barrier. Because it is only two true amino-acid residues long, it sits at the boundary between a peptide and a small molecule, and it is far more lipophilic than a typical research peptide.

Structure N-hexanoyl-L-tyrosyl-L-isoleucyl-(6)-aminohexanamide
Also known as PNB-0408, Dihexa, N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide
CAS number 1401708-83-5
Molecular formula / weight C27H44N4O5 · ≈ 504.7 g/mol
Parent peptide Angiotensin IV (Val-Tyr-Ile-His-Pro-Phe)
Proposed target HGF / c-Met signaling (potentiation of hepatocyte growth factor)
Solubility DMSO, ethanol; limited in water

What the literature has studied

Origin in the angiotensin IV literature

Angiotensin IV, a fragment of the angiotensin peptide cascade, was reported in the 1990s and 2000s to improve performance in rodent memory tasks when delivered directly into the brain, but it is degraded within minutes in circulation. The Washington State group spent years making shortened, protected analogs (Nle1-angiotensin IV, then the “norleual” series) to find one that was both stable and able to reach the brain after systemic or oral delivery. Dihexa was the outcome of that program.

Rat cognition models

The principal paper (McCoy et al., Journal of Pharmacology and Experimental Therapeutics, 2013) reported that Dihexa was stable in blood and crossed the blood–brain barrier in rats, and that oral or intraperitoneal administration improved performance in a water-maze spatial-learning task in rats whose memory had been impaired with scopolamine, and in aged rats. The same paper reported increased dendritic spine density in cultured hippocampal neurons exposed to the compound.

Proposed mechanism: HGF and c-Met

A 2014 paper (Benoist et al., JPET) proposed that Dihexa and related analogs act by binding hepatocyte growth factor (HGF) and enhancing its activation of the receptor tyrosine kinase c-Met, which in neurons promotes synapse formation. In that work the cognitive and spinogenic effects were blocked by an HGF antagonist or by c-Met knockdown. This is the mechanism most secondary sources quote, and it comes from the same group as the compound.

Human data

There are none. No clinical trial of Dihexa has been registered or published. Claims about effects in people are extrapolations from rat behavior and cultured neurons.

What the literature has not shown, and one specific caution

The evidence base is small and comes almost entirely from the originating laboratory; independent replication of the behavioral findings is limited. Pharmacokinetics beyond the rat, long-term effects and off-target activity are uncharacterized. One point deserves a specific mention for anyone designing experiments: c-Met is a proto-oncogene, and sustained HGF/c-Met activation is a recognized driver of tumor growth and invasion in several cancer types. The authors themselves raised this as a consideration for any future development. In a research setting this is a reason to include appropriate controls and to treat the compound as an uncharacterized growth-factor potentiator, not as a benign reagent.

How Dihexa is supplied for research

Quantum Peptides supplies Dihexa (PNB-0408), 8 mg capsules. Every lot is tested by an independent US laboratory for identity by mass spectrometry and purity by HPLC, with the certificate linked on the product page. Because Dihexa has a defined molecular mass (≈504.7), the certificate’s observed mass is the quickest identity check; our guide to reading a certificate of analysis explains the rest of the document.

Handling and storage

Dihexa’s hexanoyl and aminohexanoyl groups make it considerably more lipophilic than a conventional research peptide, which is the point of the design but also changes how it is handled. It dissolves readily in DMSO or ethanol and only sparingly in water; for in-vitro work, make a concentrated DMSO stock and dilute into medium, keeping the final DMSO concentration within the tolerance of the cell line. It is not reconstituted with bacteriostatic water in the way a lyophilized peptide is. Store the solid at or below room temperature, dry and protected from light; store solutions frozen in single-use portions. The peptide storage guide covers general practice; the DMSO-stock approach is the main difference for this compound.

Frequently asked questions

Is Dihexa a peptide?

Partly. It contains a tyrosine–isoleucine dipeptide, but its two six-carbon end groups make it behave more like a lipophilic small molecule than a typical peptide. It is often called a “peptide-like” or peptidomimetic compound.

What is PNB-0408?

The development code for Dihexa used in the original Washington State University publications.

What is the CAS number and molecular weight of Dihexa?

CAS 1401708-83-5; C27H44N4O5, about 504.7 g/mol.

How does Dihexa work?

The proposed mechanism, from the originating laboratory, is that it binds hepatocyte growth factor and enhances HGF’s activation of the c-Met receptor. This has been shown in cell and rat work; it has not been tested in humans.

Why is c-Met activation a concern?

c-Met is a proto-oncogene; sustained HGF/c-Met signaling drives growth and invasion in several cancers. That makes appropriate controls important in any experiment using a c-Met potentiator.

Can I buy Dihexa for human use?

No. Quantum Peptides products are supplied for in-vitro and preclinical laboratory research only, not for human or veterinary use.

References

  1. McCoy AT, Benoist CC, Wright JW, et al. Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents. Journal of Pharmacology and Experimental Therapeutics. 2013.
  2. Benoist CC, Kawas LH, Zhu M, et al. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system. Journal of Pharmacology and Experimental Therapeutics. 2014.
  3. Wright JW, Harding JW. The brain hepatocyte growth factor/c-Met receptor system: a new target for the treatment of Alzheimer’s disease. Journal of Alzheimer’s Disease. 2015.

More research guides

All research peptide guides

Quantum Peptides supplies research compounds for in-vitro and preclinical laboratory research only. Products are not for human or veterinary use. This guide summarizes published literature and is not guidance on administration of any kind.